Efficacy and safety of glecaprevir/pibrentasvir treatment for 8 weeks in treatment-naive patients with chronic hepatitis C virus infection without cirrhosis or with compensated cirrhosis: Analysis of data pooled from phase 2 and 3 studies
Publication
, Conference
Zuckerman, E; Gutierrez, J; Ustianowski, A; Naggie, S; Caruntu, FA; Ravendhran, N; Sigal, S; Barrett, L; Cohen, S; Crown, E; Dylla, D; Wang, S ...
Published in: JOURNAL OF HEPATOLOGY
April 1, 2019
Duke Scholars
Published In
JOURNAL OF HEPATOLOGY
EISSN
1600-0641
ISSN
0168-8278
Publication Date
April 1, 2019
Volume
70
Issue
1
Start / End Page
E251 / E251
Location
Vienna, AUSTRIA
Publisher
ELSEVIER
Conference Name
International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL)
Related Subject Headings
- Gastroenterology & Hepatology
- 3202 Clinical sciences
- 1117 Public Health and Health Services
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Zuckerman, E., Gutierrez, J., Ustianowski, A., Naggie, S., Caruntu, F. A., Ravendhran, N., … Bruno, S. (2019). Efficacy and safety of glecaprevir/pibrentasvir treatment for 8 weeks in treatment-naive patients with chronic hepatitis C virus infection without cirrhosis or with compensated cirrhosis: Analysis of data pooled from phase 2 and 3 studies. In JOURNAL OF HEPATOLOGY (Vol. 70, pp. E251–E251). Vienna, AUSTRIA: ELSEVIER.
Zuckerman, Eli, Julio Gutierrez, Andrew Ustianowski, Susanna Naggie, Florin Alexandru Caruntu, Natarajan Ravendhran, Samuel Sigal, et al. “Efficacy and safety of glecaprevir/pibrentasvir treatment for 8 weeks in treatment-naive patients with chronic hepatitis C virus infection without cirrhosis or with compensated cirrhosis: Analysis of data pooled from phase 2 and 3 studies.” In JOURNAL OF HEPATOLOGY, 70:E251–E251. ELSEVIER, 2019.
Zuckerman E, Gutierrez J, Ustianowski A, Naggie S, Caruntu FA, Ravendhran N, et al. Efficacy and safety of glecaprevir/pibrentasvir treatment for 8 weeks in treatment-naive patients with chronic hepatitis C virus infection without cirrhosis or with compensated cirrhosis: Analysis of data pooled from phase 2 and 3 studies. In: JOURNAL OF HEPATOLOGY. ELSEVIER; 2019. p. E251–E251.
Zuckerman, Eli, et al. “Efficacy and safety of glecaprevir/pibrentasvir treatment for 8 weeks in treatment-naive patients with chronic hepatitis C virus infection without cirrhosis or with compensated cirrhosis: Analysis of data pooled from phase 2 and 3 studies.” JOURNAL OF HEPATOLOGY, vol. 70, no. 1, ELSEVIER, 2019, pp. E251–E251.
Zuckerman E, Gutierrez J, Ustianowski A, Naggie S, Caruntu FA, Ravendhran N, Sigal S, Barrett L, Cohen S, Crown E, Dylla D, Fredrick L, Wang S, Porcalla A, Mensa F, Bruno S. Efficacy and safety of glecaprevir/pibrentasvir treatment for 8 weeks in treatment-naive patients with chronic hepatitis C virus infection without cirrhosis or with compensated cirrhosis: Analysis of data pooled from phase 2 and 3 studies. JOURNAL OF HEPATOLOGY. ELSEVIER; 2019. p. E251–E251.
Published In
JOURNAL OF HEPATOLOGY
EISSN
1600-0641
ISSN
0168-8278
Publication Date
April 1, 2019
Volume
70
Issue
1
Start / End Page
E251 / E251
Location
Vienna, AUSTRIA
Publisher
ELSEVIER
Conference Name
International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL)
Related Subject Headings
- Gastroenterology & Hepatology
- 3202 Clinical sciences
- 1117 Public Health and Health Services
- 1103 Clinical Sciences